PROFILES - Connect with RTRN Researchers

James Lillard
Title Professor, Dept. of Microbiology, Biochemistry, & Immunology
Faculty Rank
Degree Ph.D.
Institution Morehouse School of Medicine
Department Microbiology, Biochemistry, & Immunology
Clusters Infectious and Immunological Diseases
Address
Morehouse School of Medicine
720 Westview Drive SW
Hugh Gloster Building
City Atlanta
State GA
Postal Code 30310
Telephone 404-752-1863
Fax
Email
QR Barcode

Narrative icon

 
Not Available

NIH Awarded Grants icon

  Research projects funded by the National Institutes of Health (NIH), the Centers for Disease Control (CDC), the Food and Drug Administration (FDA), and the Department of Veterans Affairs (VA)

Loading
Please wait
1.
2017Morehouse School of Medicine/Tuskegee University/UAB Comprehensive Cancer Center Partnership5U54CA118638-12
2.
2017Bioethics Shared Resource5U54CA118638-12
3.
20172/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership5U54CA118623-12
4.
2017Admin Core5U54CA118638-12
5.
2017CD24-dependent Inactivation of Mutant p53 in Metastatic Castration-resistant Prostate Cancer5U54CA118638-12
6.
2016Admin Core2U54CA118638-11
7.
2016Morehouse School of Medicine/Tuskegee University/UAB Comprehensive Cancer Center Partnership2U54CA118638-11
8.
2016CD24-dependent Inactivation of Mutant p53 in Metastatic Castration-resistant Prostate Cancer2U54CA118638-11
9.
20163/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership2U54CA118948-11
10.
20163/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership3U54CA118948-11S1
11.
2016Admin supplement2U54CA118948-11
12.
2016Bioethics Shared Resource2U54CA118638-11
13.
20162/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership2U54CA118623-11
14.
2015Morehouse School of Med/Tuskegee U/UAB Comp. Cancer Center Partnership5U54CA118638-10
15.
2014Morehouse School of Med/Tuskegee U/UAB Comp. Cancer Center Partnership3U54CA118638-09S1
16.
2014Treatment of Colitis using a Novel CXCR3 Biologic Antagonist5R43DK096857-02
17.
2014Novel pharmacogenomic approach for identifying T cell epitopes in replacement FVI1R41MD008809-01
18.
2014Morehouse School of Med/Tuskegee U/UAB Comp. Cancer Center Partnership5U54CA118638-09
19.
2013Treatment of Colitis using a Novel CXCR3 Biologic Antagonist1R43DK096857-01A1
20.
2013Morehouse School of Med/Tuskegee U/UAB Comp. Cancer Center Partnership3U54CA118638-08S1
21.
2013Evaluation of the Antigenicity of Black Restricted FVIII Haplotypes and Haplotype1R41MD008156-01A1
22.
2013Morehouse School of Med/Tuskegee U/UAB Comp. Cancer Center Partnership5U54CA118638-08
23.
2012Morehouse School of Med/Tuskegee U/UAB Comp. Cancer Center Partnership3U54CA118638-07S1
24.
2012Morehouse School of Med/Tuskegee U/UAB Comp. Cancer Center Partnership5U54CA118638-07
25.
2011Morehouse School of Med/Tuskegee U/UAB Comp. Cancer Center Partnership2U54CA118638-06
26.
2011CELLS AND TISSUES2G12RR003034-26
27.
2010CELLS AND TISSUES5G12RR003034-25
28.
2007Role of RANTES in Pneumococcal Immunopathogenesis5R01AI057808-05
29.
2006Role of RANTES in Pneumococcal Immunopathogenesis5R01AI057808-03
30.
2006ROLE OF CHEMOKINES IN MUCOSAL IMMUNITY: ORAL, RESPIRATORY &UROGENITAL PATHOGENS2G12RR003034-21
31.
2006Role of RANTES in Pneumococcal Immunopathogenesis7R01AI057808-04
32.
2005Role of RANTES in Pneumococcal Immunopathogenesis5R01AI057808-02
33.
2005ROLE OF CHEMOKINES IN MUCOSAL IMMUNITY: ORAL, RESPIRATORY &UROGENITAL PATHOGENS5G12RR003034-20
34.
2004ROLE OF CHEMOKINES IN MUCOSAL IMMUNITY: ORAL, RESPIRATORY &UROGENITAL PATHOGENS5G12RR003034-19
35.
2004Role of RANTES in Pneumococcal Immunopathogenesis1R01AI057808-01A1
36.
2002ROLE OF CHEMOKINES IN T CELL MEDIATED COLITIS5R03DK058967-03
37.
2001ROLE OF CHEMOKINES IN T CELL MEDIATED COLITIS5R03DK058967-02
38.
2000ROLE OF CHEMOKINES IN T CELL MEDIATED COLITIS1R03DK058967-01

Publications icon

  Check NIH Public Access Policy Compliance

Loading
Please wait
1. Singh SK, Lillard JW, Singh R. Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer. Cancer Lett. 2018 Apr 18; 427:49-62.
2. Singh SK, Singh S, Lillard JW, Singh R. Drug delivery approaches for breast cancer. Int J Nanomedicine. 2017; 12:6205-6218.
3. Stewart T, Koval WT, Molina SA, Bock SM, Lillard JW, Ross RF, Desai TA, Koval M. Calibrated flux measurements reveal a nanostructure-stimulated transcytotic pathway. Exp Cell Res. 2017 06 15; 355(2):153-161.
4. Singh SK, Banerjee S, Acosta EP, Lillard JW, Singh R. Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/ p21WAF1/CIP1 and p27KIP1 pathway. Oncotarget. 2017 Mar 07; 8(10):17216-17228.
5. Banerjee S, Singh SK, Chowdhury I, Lillard JW, Singh R. Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer. Front Biosci (Elite Ed). 2017 03 01; 9:235-245.
6. Huang MB, Gonzalez RR, Lillard J, Bond VC. Secretion modification region-derived peptide blocks exosome release and mediates cell cycle arrest in breast cancer cells. Oncotarget. 2017 Feb 14; 8(7):11302-11315.
7. Singh SK, Lillard JW, Singh R. Molecular basis for prostate cancer racial disparities. Front Biosci (Landmark Ed). 2017 01 01; 22:428-450.
8. Kapur N, Mir H, Clark Iii CE, Krishnamurti U, Beech DJ, Lillard JW, Singh S. CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition. Br J Cancer. 2016 06 14; 114(12):1343-51.
9. Singh R, Kapur N, Mir H, Singh N, Lillard JW, Singh S. CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and avß3 integrin clustering. Oncotarget. 2016 Feb 09; 7(6):7343-53.
10. Mir H, Kapur N, Singh R, Sonpavde G, Lillard JW, Singh S. Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors. Cell Cycle. 2016; 15(6):819-26.
11. Zhang W, Yi B, Wang C, Chen D, Bae S, Wei S, Guo RJ, Lu C, Nguyen LL, Yang WH, Lillard JW, Zhang X, Wang L, Liu R. Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells. Clin Cancer Res. 2016 May 15; 22(10):2545-54.
12. Mir H, Singh R, Kloecker GH, Lillard JW, Singh S. CXCR6 expression in non-small cell lung carcinoma supports metastatic process via modulating metalloproteinases. Oncotarget. 2015 Apr 30; 6(12):9985-98.
13. Yoo W, Coughlin SS, Lillard JW. Trends in cancer incidence rates in Georgia, 1982-2011. J Ga Public Health Assoc. 2015; 5(1):96-100.
14. Gupta P, Sharma PK, Mir H, Singh R, Singh N, Kloecker GH, Lillard JW, Singh S. CCR9/CCL25 expression in non-small cell lung cancer correlates with aggressive disease and mediates key steps of metastasis. Oncotarget. 2014 Oct 30; 5(20):10170-9.
15. Yoo W, Mayberry R, Bae S, Singh K, Peter He Q, Lillard JW. A Study of Effects of MultiCollinearity in the Multivariable Analysis. Int J Appl Sci Technol. 2014 Oct; 4(5):9-19.
16. Singh R, Gupta P, Kloecker GH, Singh S, Lillard JW. Expression and clinical significance of CXCR5/CXCL13 in human non-small cell lung carcinoma. Int J Oncol. 2014 Dec; 45(6):2232-40.
17. Singh R, Gupta P, Sharma PK, Ades EW, Hollingshead SK, Singh S, Lillard JW. Prediction and characterization of helper T-cell epitopes from pneumococcal surface adhesin A. Immunology. 2014 Apr; 141(4):514-30.
18. El-Haibi CP, Sharma P, Singh R, Gupta P, Taub DD, Singh S, Lillard JW. Differential G protein subunit expression by prostate cancer cells and their interaction with CXCR5. Mol Cancer. 2013 Jun 18; 12:64.
19. El-Haibi CP, Singh R, Gupta P, Sharma PK, Greenleaf KN, Singh S, Lillard JW. Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer. J Proteomics Bioinform. 2012; 5(8):177-184.
20. Singh R, Singh S, Briles DE, Taub DD, Hollingshead SK, Lillard JW. CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes. Vaccine. 2012 Feb 01; 30(6):1181-90.
21. Moktar A, Singh R, Vadhanam MV, Ravoori S, Lillard JW, Gairola CG, Gupta RC. Cigarette smoke condensate-induced oxidative DNA damage and its removal in human cervical cancer cells. Int J Oncol. 2011 Oct; 39(4):941-7.
22. El-Haibi CP, Singh R, Sharma PK, Singh S, Lillard JW. CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation. Cell Prolif. 2011 Aug; 44(4):311-9.
23. Singh R, Lillard JW, Singh S. Chemokines: key players in cancer progression and metastasis. Front Biosci (Schol Ed). 2011 Jun 01; 3:1569-82.
24. Singh R, Stockard CR, Grizzle WE, Lillard JW, Singh S. Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer. Int J Oncol. 2011 Aug; 39(2):373-81.
25. Johnson-Holiday C, Singh R, Johnson EL, Grizzle WE, Lillard JW, Singh S. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J Surg Oncol. 2011 May 03; 9:46.
26. Johnson-Holiday C, Singh R, Johnson E, Singh S, Stockard CR, Grizzle WE, Lillard JW. CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int J Oncol. 2011 May; 38(5):1279-85.
27. Johnson EL, Singh R, Singh S, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol. 2010 Jul 22; 8:62.
28. Johnson EL, Singh R, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW, Singh S. CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion. J Ovarian Res. 2010 Jun 17; 3:15.
29. El Haibi CP, Sharma PK, Singh R, Johnson PR, Suttles J, Singh S, Lillard JW. PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells. Mol Cancer. 2010 Apr 22; 9:85.
30. VanCleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, Baumgartner RN, Lillard JW, Kittles RA, Kidd LC. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate. 2010 Mar 01; 70(4):341-52.
31. Singh R, Singh S, Sharma PK, Singh UP, Briles DE, Hollingshead SK, Lillard JW. Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A. PLoS One. 2010 Feb 25; 5(2):e9432.
32. Singh S, Singh R, Singh UP, Rai SN, Novakovic KR, Chung LW, Didier PJ, Grizzle WE, Lillard JW. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer. 2009 Nov 15; 125(10):2288-95.
33. Harrington W, Bond V, Huang MB, Powell M, Lillard J, Manne U, Bumpers H. HIV Nef-M1 Effects on Colorectal Cancer Growth in Tumor-induced Spleens and Hepatic Metastasis. Mol Cell Pharmacol. 2009 Aug 05; 1(2):85-91.
34. Singh S, Singh R, Sharma PK, Singh UP, Rai SN, Chung LW, Cooper CR, Novakovic KR, Grizzle WE, Lillard JW. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett. 2009 Sep 28; 283(1):29-35.
35. Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009 Jun; 86(3):215-23.
36. Singh S, Bond VC, Powell M, Singh UP, Bumpers HL, Grizzle WE, Lillard JW. CXCR4-gp120-IIIB interactions induce caspase-mediated apoptosis of prostate cancer cells and inhibit tumor growth. Mol Cancer Ther. 2009 Jan; 8(1):178-84.
37. Zuba-Surma EK, Kucia M, Wu W, Klich I, Lillard JW, Ratajczak J, Ratajczak MZ. Very small embryonic-like stem cells are present in adult murine organs: ImageStream-based morphological analysis and distribution studies. Cytometry A. 2008 Dec; 73A(12):1116-27.
38. Sakthivel SK, Singh UP, Singh S, Taub DD, Novakovic KR, Lillard JW. CXCL10 blockade protects mice from cyclophosphamide-induced cystitis. J Immune Based Ther Vaccines. 2008 Oct 28; 6:6.
39. Sakthivel SK, Singh UP, Singh S, Taub DD, Igietseme JU, Lillard JW. CCL5 regulation of mucosal chlamydial immunity and infection. BMC Microbiol. 2008 Aug 13; 8:136.
40. Singh R, Singh S, Lillard JW. Past, present, and future technologies for oral delivery of therapeutic proteins. J Pharm Sci. 2008 Jul; 97(7):2497-523.
41. Singh UP, Singh R, Singh S, Karls RK, Quinn FD, Taub DD, Lillard JW. CXCL10+ T cells and NK cells assist in the recruitment and activation of CXCR3+ and CXCL11+ leukocytes during Mycobacteria-enhanced colitis. BMC Immunol. 2008 Jun 04; 9:25.
42. Singh UP, Singh S, Singh R, Cong Y, Taub DD, Lillard JW. CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J Interferon Cytokine Res. 2008 Jan; 28(1):31-43.
43. Zuba-Surma EK, Kucia M, Abdel-Latif A, Dawn B, Hall B, Singh R, Lillard JW, Ratajczak MZ. Morphological characterization of very small embryonic-like stem cells (VSELs) by ImageStream system analysis. J Cell Mol Med. 2008 Jan-Feb; 12(1):292-303.
44. Singh UP, Venkataraman C, Singh R, Lillard JW. CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication. Endocr Metab Immune Disord Drug Targets. 2007 Jun; 7(2):111-23.
45. Singh UP, Singh S, Singh R, Karls RK, Quinn FD, Potter ME, Lillard JW. Influence of Mycobacterium avium subsp. paratuberculosis on colitis development and specific immune responses during disease. Infect Immun. 2007 Aug; 75(8):3722-8.
46. Zuba-Surma EK, Kucia M, Abdel-Latif A, Lillard JW, Ratajczak MZ. The ImageStream System: a key step to a new era in imaging. Folia Histochem Cytobiol. 2007; 45(4):279-90.
47. Fang Z, Miao Y, Ding X, Deng H, Liu S, Wang F, Zhou R, Watson C, Fu C, Hu Q, Lillard JW, Powell M, Chen Y, Forte JG, Yao X. Proteomic identification and functional characterization of a novel ARF6 GTPase-activating protein, ACAP4. Mol Cell Proteomics. 2006 Aug; 5(8):1437-49.
48. Palaniappan R, Singh S, Singh UP, Singh R, Ades EW, Briles DE, Hollingshead SK, Royal W, Sampson JS, Stiles JK, Taub DD, Lillard JW. CCL5 modulates pneumococcal immunity and carriage. J Immunol. 2006 Feb 15; 176(4):2346-56.
49. Sarfo BY, Armah HB, Irune I, Adjei AA, Olver CS, Singh S, Lillard JW, Stiles JK. Plasmodium yoelii 17XL infection up-regulates RANTES, CCR1, CCR3 and CCR5 expression, and induces ultrastructural changes in the cerebellum. Malar J. 2005 Dec 16; 4:63.
50. Renninger ML, Seymour R, Lillard JW, Sundberg JP, HogenEsch H. Increased expression of chemokines in the skin of chronic proliferative dermatitis mutant mice. Exp Dermatol. 2005 Dec; 14(12):906-13.
51. Barr EL, Ouburg S, Igietseme JU, Morré SA, Okwandu E, Eko FO, Ifere G, Belay T, He Q, Lyn D, Nwankwo G, Lillard JW, Black CM, Ananaba GA. Host inflammatory response and development of complications of Chlamydia trachomatis genital infection in CCR5-deficient mice and subfertile women with the CCR5delta32 gene deletion. J Microbiol Immunol Infect. 2005 Aug; 38(4):244-54.
52. Palaniappan R, Singh S, Singh UP, Sakthivel SK, Ades EW, Briles DE, Hollingshead SK, Paton JC, Sampson JS, Lillard JW. Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage. Infect Immun. 2005 Feb; 73(2):1006-13.
53. Bumpers HL, Huang MB, Powell M, Grizzle WE, Lillard JW, Okoli J, Bond VC. Effects of HIV-1 Nef, a cytotoxic viral protein, on the growth of primary colorectal cancer. Cancer Biol Ther. 2005 Jan; 4(1):65-9.
54. Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JW. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res. 2004 Dec 15; 10(24):8743-50.
55. Singh S, Singh UP, Grizzle WE, Lillard JW. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest. 2004 Dec; 84(12):1666-76.
56. Singh UP, Singh S, Ravichandran P, Taub DD, Lillard JW. Viral macrophage-inflammatory protein-II: a viral chemokine that differentially affects adaptive mucosal immunity compared with its mammalian counterparts. J Immunol. 2004 Nov 01; 173(9):5509-16.
57. Singh UP, Singh S, Boyaka PN, McGhee JR, Lillard JW. Granulocyte chemotactic protein-2 mediates adaptive immunity in part through IL-8Rbeta interactions. J Leukoc Biol. 2004 Dec; 76(6):1240-7.
58. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, Lillard JW, Taub DD. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest. 2004 Jul; 114(1):57-66.
59. Sarfo BY, Singh S, Lillard JW, Quarshie A, Gyasi RK, Armah H, Adjei AA, Jolly P, Stiles JK. The cerebral-malaria-associated expression of RANTES, CCR3 and CCR5 in post-mortem tissue samples. Ann Trop Med Parasitol. 2004 Apr; 98(3):297-303.
60. Singh UP, Singh S, Iqbal N, Weaver CT, McGhee JR, Lillard JW. IFN-gamma-inducible chemokines enhance adaptive immunity and colitis. J Interferon Cytokine Res. 2003 Oct; 23(10):591-600.
61. Singh UP, Singh S, Taub DD, Lillard JW. Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10-/- mice. J Immunol. 2003 Aug 01; 171(3):1401-6.
62. Lillard JW, Singh UP, Boyaka PN, Singh S, Taub DD, McGhee JR. MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood. 2003 Feb 01; 101(3):807-14.
63. Lillard JW, Boyaka PN, Singh S, McGhee JR. Salmonella-mediated mucosal cell-mediated immunity. Cell Mol Biol (Noisy-le-grand). 2001 Nov; 47(7):1115-20.
64. Lillard JW, Boyaka PN, Taub DD, McGhee JR. RANTES potentiates antigen-specific mucosal immune responses. J Immunol. 2001 Jan 01; 166(1):162-9.
65. Jones HA, Lillard JW, Perry RD. HmsT, a protein essential for expression of the haemin storage (Hms+) phenotype of Yersinia pestis. Microbiology. 1999 Aug; 145 ( Pt 8):2117-28.
66. Lillard JW, Boyaka PN, Hedrick JA, Zlotnik A, McGhee JR. Lymphotactin acts as an innate mucosal adjuvant. J Immunol. 1999 Feb 15; 162(4):1959-65.
67. Lillard JW, Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR. Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc Natl Acad Sci U S A. 1999 Jan 19; 96(2):651-6.
68. Lillard JW, Bearden SW, Fetherston JD, Perry RD. The haemin storage (Hms+) phenotype of Yersinia pestis is not essential for the pathogenesis of bubonic plague in mammals. Microbiology. 1999 Jan; 145 ( Pt 1):197-209.
69. Boyaka PN, Lillard JW, McGhee J. Interleukin 12 and innate molecules for enhanced mucosal immunity. Immunol Res. 1999; 20(3):207-17.
70. Lillard JW, McGhee JR. Adjuvants or live delivery systems for the characterization of mucosal T helper subset responses. Res Immunol. 1997 Oct-Dec; 148(8-9):520-7.
71. Lillard JW, Fetherston JD, Pedersen L, Pendrak ML, Perry RD. Sequence and genetic analysis of the hemin storage (hms) system of Yersinia pestis. Gene. 1997 Jul 01; 193(1):13-21.
72. Fetherston JD, Lillard JW, Perry RD. Analysis of the pesticin receptor from Yersinia pestis: role in iron-deficient growth and possible regulation by its siderophore. J Bacteriol. 1995 Apr; 177(7):1824-33.

Research Resources icon

Funding Opportunities icon

Browse active NIH & NSF funding opportunities, requests for applications (RFAs), and program announcements (PAs)

Publications Timeline

Top MeSH Keywords

Tree Map of Keyword Semantic Groups (Categories)

Left-click a node to move down the tree, right-click the graph to move back up the tree

Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile:
 
Keyword
Last Name
Institution
 
See all (12) people See all (60) people
Feedback

RTRN Collaboration and Professional Networking Feedback